Literature DB >> 15221962

Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix.

Heidi Lyng1, Marzieh Beigi, Debbie H Svendsrud, Odd T Brustugun, Trond Stokke, Gunnar B Kristensen, Kolbein Sundfør, Ane Skjønsberg, Paula M De Angelis.   

Abstract

Intratumor heterogeneity in chromosomal aberrations is believed to represent a major challenge in the treatment of cancer. The aim of our work was to assess the chromosomal heterogeneity of advanced cervical carcinomas and to distinguish aberrations that had occurred at a late stage of the disease from early events. A total of 55 biopsies, sampled from 2-4 different sites within 20 tumors, were analyzed by use of comparative genomic hybridization. Heterogeneous aberrations were identified as those present in at least 1 of the biopsies and which were not seen, nor seen as a tendency, in the others of the same tumor. The homogeneous aberrations were those seen in all biopsies of the tumor. The most frequent homogeneous aberrations were gain of 3q (65%), 20q (65%) and 5p (50%), indicating that these are early events in the development of the disease. Chromosomal heterogeneity was observed in 11 tumors. The most frequent heterogeneous aberrations were loss of 4p14-q25 (60% of 10 cases with this aberration), and gain of 2p22-pter (50% of 6 cases), 11qcen-q13 (33% of 9 cases) and 8q (27% of 11 cases), suggesting that these events promote progression at a later stage. Many of the heterogeneous regions contained genes known to influence the prognosis of cervical cancer, such as 7p (EGFR), 8q (c-MYC), 11qcen-q13 (CCND1) and 17q (ERBB2). Three evolution sequences for the subpopulations in the heterogeneous tumors were identified: a serial, a parallel and a mixed sequence. In 2 tumors with a serial sequence, it was indicated that the aberrations +8 and -X had occurred after the other heterogeneous aberrations and hence were the aberrations most recently formed. Our results suggest pronounced chromosomal instability in advanced cervical carcinomas. Moreover, aggressive and treatment-resistant subpopulations may emerge at a late stage and possibly contribute to a poor prognosis of the advanced stages. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221962     DOI: 10.1002/ijc.20258

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Authors:  Ankur Chakravarthy; Ian Reddin; Stephen Henderson; Cindy Dong; Nerissa Kirkwood; Maxmilan Jeyakumar; Daniela Rothschild Rodriguez; Natalia Gonzalez Martinez; Jacqueline McDermott; Xiaoping Su; Nagayasau Egawa; Christina S Fjeldbo; Vilde Eide Skingen; Heidi Lyng; Mari Kyllesø Halle; Camilla Krakstad; Afschin Soleiman; Susanne Sprung; Matt Lechner; Peter J I Ellis; Mark Wass; Martin Michaelis; Heidi Fiegl; Helga Salvesen; Gareth J Thomas; John Doorbar; Kerry Chester; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

2.  Putative precursor cancer cells in human colorectal cancer tissue.

Authors:  Teodora E Goranova; Masayuki Ohue; Kikuya Kato
Journal:  Int J Clin Exp Pathol       Date:  2008-07-14

3.  Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors.

Authors:  Teodora Evgenieva Goranova; Masayuki Ohue; Yutaro Shimoharu; Kikuya Kato
Journal:  Clin Exp Metastasis       Date:  2011-03-05       Impact factor: 5.150

4.  Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer.

Authors:  Heidi Lyng; Runar S Brøvig; Debbie H Svendsrud; Ruth Holm; Olav Kaalhus; Kjetil Knutstad; Halldis Oksefjell; Kolbein Sundfør; Gunnar B Kristensen; Trond Stokke
Journal:  BMC Genomics       Date:  2006-10-20       Impact factor: 3.969

5.  Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer.

Authors:  Karina L Mine; Natalia Shulzhenko; Anatoly Yambartsev; Mark Rochman; Gerdine F O Sanson; Malin Lando; Sudhir Varma; Jeff Skinner; Natalia Volfovsky; Tao Deng; Sylvia M F Brenna; Carmen R N Carvalho; Julisa C L Ribalta; Michael Bustin; Polly Matzinger; Ismael D C G Silva; Heidi Lyng; Maria Gerbase-DeLima; Andrey Morgun
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

6.  Developing a prognostic micro-RNA signature for human cervical carcinoma.

Authors:  Christine How; Melania Pintilie; Jeff P Bruce; Angela B Y Hui; Blaise A Clarke; Philip Wong; Shaoming Yin; Rui Yan; Daryl Waggott; Paul C Boutros; Anthony Fyles; David W Hedley; Richard P Hill; Michael Milosevic; Fei-Fei Liu
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

7.  Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA.

Authors:  Katrin Carow; Mandy Gölitz; Maria Wolf; Norman Häfner; Lars Jansen; Heike Hoyer; Elisabeth Schwarz; Ingo B Runnebaum; Matthias Dürst
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

8.  Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer.

Authors:  Malin Lando; Marit Holden; Linn C Bergersen; Debbie H Svendsrud; Trond Stokke; Kolbein Sundfør; Ingrid K Glad; Gunnar B Kristensen; Heidi Lyng
Journal:  PLoS Genet       Date:  2009-11-13       Impact factor: 5.917

9.  GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data.

Authors:  Heidi Lyng; Malin Lando; Runar S Brøvig; Debbie H Svendsrud; Morten Johansen; Eivind Galteland; Odd T Brustugun; Leonardo A Meza-Zepeda; Ola Myklebost; Gunnar B Kristensen; Eivind Hovig; Trond Stokke
Journal:  Genome Biol       Date:  2008-05-23       Impact factor: 13.583

10.  Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer.

Authors:  Sabrina A H M van den Tillaart; Wim E Corver; Dina Ruano Neto; Natalja T ter Haar; Jelle J Goeman; J Baptist M Z Trimbos; Gertjan J Fleuren; Jan Oosting
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.